Immunic, Inc. (NASDAQ:IMUX - Free Report) - Equities research analysts at B. Riley lowered their FY2024 earnings per share (EPS) estimates for shares of Immunic in a research note issued to investors on Tuesday, November 26th. B. Riley analyst W. Wood now anticipates that the company will post earnings of ($0.97) per share for the year, down from their previous forecast of ($0.93). B. Riley has a "Buy" rating and a $6.00 price objective on the stock. The consensus estimate for Immunic's current full-year earnings is ($0.93) per share. B. Riley also issued estimates for Immunic's Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.35) EPS and FY2025 earnings at ($0.80) EPS.
IMUX has been the topic of a number of other research reports. EF Hutton Acquisition Co. I raised Immunic to a "strong-buy" rating in a research note on Monday, September 16th. Leerink Partnrs raised Immunic to a "strong-buy" rating in a research note on Monday, September 9th. Leerink Partners reissued an "outperform" rating and issued a $5.00 price objective on shares of Immunic in a research note on Monday, September 9th. StockNews.com cut Immunic from a "hold" rating to a "sell" rating in a report on Monday, November 11th. Finally, HC Wainwright assumed coverage on Immunic in a report on Monday. They issued a "buy" rating and a $10.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Immunic has an average rating of "Buy" and a consensus price target of $11.80.
Get Our Latest Report on Immunic
Immunic Stock Up 5.3 %
Shares of IMUX traded up $0.06 during midday trading on Thursday, reaching $1.20. The stock had a trading volume of 720,334 shares, compared to its average volume of 899,706. Immunic has a 52 week low of $0.97 and a 52 week high of $2.11. The firm's 50 day moving average price is $1.37 and its 200-day moving average price is $1.34.
Insider Buying and Selling at Immunic
In other news, Director Richard Alan Rudick bought 87,300 shares of the stock in a transaction on Tuesday, November 12th. The shares were purchased at an average price of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the purchase, the director now directly owns 87,300 shares of the company's stock, valued at $100,395. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 3.00% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the company. State Street Corp grew its stake in Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company's stock valued at $276,000 after purchasing an additional 11,642 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Immunic in the first quarter worth about $25,000. Jane Street Group LLC lifted its position in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after buying an additional 38,553 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock worth $169,000 after buying an additional 42,383 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Immunic by 100.7% in the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company's stock worth $4,480,000 after buying an additional 1,703,047 shares during the last quarter. Hedge funds and other institutional investors own 51.82% of the company's stock.
Immunic Company Profile
(
Get Free Report)
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Further Reading
Before you consider Immunic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.
While Immunic currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
